The association between inflammation, infection, and venous thrombosis has long been
recognized; yet, only in the last decades have we begun to understand the mechanisms …

Venous thromboembolism is a very common and costly health problem worldwide.
Anticoagulant treatment for VTE is imperfect: all have the potential for significant bleeding …

Deep vein thrombosis (DVT) is a major cause of cardiovascular death. The sequence of
events that promote DVT remains obscure, largely as a result of the lack of an appropriate …

Targeted drug delivery to disease-associated activated neutrophils can provide novel
therapeutic opportunities while avoiding systemic effects on immune functions. We created a …

Microvesicles (MVs) circulating in the blood are small vesicles (100–1,000 nm in diameter)
derived from membrane blebs of cells such as activated platelets, endothelial cells, and …

Background Although common, little is known about factors associated with peripherally
inserted central catheter-related deep vein thrombosis (PICC-DVT). To better guide …

This practical guidance, endorsed by the Brazilian Society of Thrombosis and Hemostasis
and The Brazilian Society of Angiology and Vascular Surgery, the International Union of …

Microparticles (MPs) are submicron vesicles released from the plasma membrane of
eukaryotic cells in response to activation or apoptosis. MPs are known to be involved in …

Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary
embolism. The 2009 JUPITER trial showed a significant decrease in DVT in non …

Venous thromboembolism (VTE) is the third leading cardiovascular cause of death and is
conventionally treated with anticoagulants that directly antagonize coagulation. However …